XOMA Corporation (XOMAP)
XOMA Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
XOMA Corporation (XOMAP) is a Biotechnology company based in US with a market capitalization of $307M. Revenue grew 83.1% year-over-year and the company generated $2.9M in free cash flow. This page tracks XOMAP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 13 employees · IPO Dec 16, 2020
Valuation
Valuation & price
$25.30 · as of May 17, 2026 · -7.2% vs 52w high
14.3
P/E ratio
Latest-FY diluted EPS
2.95
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$307M
Market cap
83.1%
Revenue growth (YoY)
94.3%
Gross margin
$2.9M
Free cash flow (USD)
$48.6M
Net debt
53.7%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is XOMA Corporation's market cap?
XOMA Corporation (XOMAP) has a market capitalization of $307M.
What is XOMAP's P/E ratio?
XOMAP trades at a price-to-earnings ratio of 14.3, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is XOMAP's price-to-book (P/B) ratio?
XOMAP trades at 2.95 times book value per share.
Are insiders buying XOMAP stock?
SEC Form 4 filings show no open-market insider buys at XOMA Corporation in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.